|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
The trouble with health statistics [Cancer World]
|
|
|
|
|
|
"It
is crucial to understand how even simple percentages can be manipulated
to tell the desired story, for example using relative rather than
absolute risks, mortality rates rather than survival rates, or quoting
increased 5-year survival rates when all that has happened is that the
age at diagnosis has been reduced.”
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
BMS' Opdivo fails to win over NICE as adjuvant melanoma therapy [Pharmafile]
|
|
|
|
|
|
Because
of this doubt over the robustness of the data, “cost-effectiveness
estimates for nivolumab are uncertain”, the institute added. Not only
does this make it impossible for the drug to be accessible on the NHS at
its current price, but NICE also confirmed that Opdivo would also not
be made available on the Cancer Drugs Fund (CDF).
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.6 ESMO
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10 Politiques
|
|
|
|
6.12 Ethique
|
|
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|
|
6.6 Publications
|
|
|
|
|
6.9 Controverses
|
|
|
|